Reactive arthritis (ReA) is a recognised complication of Yersiniosis. As an aseptic arthritis, it does not require antibiotic treatment and is typically self-limiting. However, some patients develop a persistent or chronic course that does not resolve with standard first-line measures.
First-line management addresses joint pain with NSAIDs or glucocorticosteroids — and, when active yersiniosis infection is documented, with ciprofloxacin. The target is faster remission and meaningful relief of joint pain within three months.
When that target is not reached and joint symptoms persist, escalation to a next-line approach is warranted.
Chronic reactive arthritis that does not respond adequately to initial therapy may require the introduction of disease-modifying antirheumatic drugs (DMARDs) — a class of therapy that targets persistent joint inflammation more durably than symptomatic agents alone. The specific agent and sequence are covered in the full protocol.
DOI: 10.3390/microorganisms13051133
Since ReA is an aseptic arthritis, it does not require antibiotic treatment and is usually self-limiting.
Joint pain may well respond to NSAIDs or glucocorticosteroids, but chronic ReA may require the introduction of disease-modifying antirheumatic drugs (DMARDs).
The drug used as the first choice is sulfasalazine.
View source ↗